CagriSema represents a dual-agonist approach, combining two powerful peptides to target multiple pathways involved in appetite and metabolism. This product is a blend of Cagrilintide and Semaglutide, intended for laboratory research.

1. Cagrilintide: This component is a long-acting amylin analogue. Amylin is a hormone co-secreted with insulin that helps to reduce food intake by promoting a feeling of fullness (satiety) and slowing gastric emptying.

2. Semaglutide: This component is a well-known glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the GLP-1 hormone, which stimulates insulin secretion, inhibits glucagon release, and signals satiety to the brain, thereby reducing appetite.

By combining these two distinct mechanisms, CagriSema is being studied for its potential to produce significantly greater weight loss and improved glycemic control than either compound alone.

Chemical & Physical Properties (for the combined product):

• Product: CagriSema (Cagrilintide + Semaglutide Blend)

• Quantity: 10 mg total

• Appearance: White Lyophilized Powder

• Purity: Typically ≥98% (via HPLC)

• Storage: Store lyophilized powder at -20°C. Once reconstituted, store in a refrigerator at 2-8°C.

Active Component CAS Numbers:

• Cagrilintide CAS Number: 1415456-99-3

• Semaglutide CAS Number: 910463-68-2

For Research Use Only. This product is a blend of two distinct peptides. It is not intended for diagnostic, therapeutic, or human use.